Clinical Trial Update: Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and efficacy in patients with recurrent glioblastoma multiforme (Grade 4 malignant brain tumor) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Recurrent Glioblastoma Multiforme | Phase 2 | Status: COMPLETED